Bright Minds
Building an AI neuropsychologist
The Problem
1 in 3 children struggle with a developmental, learning, or behavioral disorder (such as ADHD or dyslexia). But prompt diagnosis is only accessible to the wealthy.
Stay in-network
Long Wait Times
Parents wait up to 16 months for diagnosis
Go out-of-network
High Costs
Neuropsychological assessments cost up to $7,000
Our Solution
Democratize screening, diagnosis, and carecare.
On-Demand Screening and Testing
Accessible 24/7 online AI-driven assessments
Affordable Pricing
Just $100 for full-service testing, updated every year.
Adaptive Care
If therapies or medicines stop working, our AI will figure out why and set you on a new schedule.
How It Works
1
1. Screening driven by clinical voice AI
Start with a clinically validated, AI-first, online assessment – no appointment needed.
2
2. Interactive feedback
Parents and patients access reports immediately, and speak with our clinical AI to better understand their results.
3
3. AI-assisted clinician diagnosis
Our AI will reach out to a clinician on your behalf for prompt, affordable diagnosis using the results of our screening.
4
4. Adaptive care
Clinicians diagnose, refer, and suggest care paths based on our testing. If necessary our AI will administer follow-up tests to ensure you get the highest standard of care.
Go-To-Market Strategy
Pilot with Clinics
Pilot our software as a clinical decision support tool for fast iteration; use pilot study to guarantee product reliability.
Clinical Validation
Certify as a class 2 medical device to allow for more AI-driven actions with hands-off clinicians
To Parents through Clinics
SLG motion (introductions and academic conferences) to build rapport with clinics; PLG motion to get our name out there
Market Opportunity
$4bn
US children with developmental conditions
Expanded market including autism spectrum and learning disorders
$20bn
Americans with neuropsychological conditions
Total addressable market across all ages and conditions
Competitive Landscape
Regulation
Initial Clinical Offering
Our initial offering requires is a clinical decision support tool. This does not require FDA approval. Additionally, our AI is HIPAA-compliant.
Catalyzing Innovation
Short term, we intend for AI to supplement, not replace, clinical judgment. Thus, we do not intend to pursue higher tiers of regulatory approval, which will facilitate rapid iteration and innovation.
Future Diagnostic Services
We intend to slowly expand the scope of our AI into diagnostics, which will require FDA SaMD certification as a class 2 medical device. This process is expected to require 6 months and $100k.
Our regulatory strategy maximizes speed-to-market while maintaining compliance at every stage of growth.
Traction & Roadmap
Bright is rapidly gaining momentum in revolutionizing mental health diagnostics.
Team Formation
Completed
Recruited two specialized teammates and secured three industry advisors.
Proof-of-Concept
Completed
Completed initial application demonstrating our AI assessment capability.
First Customer
In Progress
Crafted a pilot agreement with our lead customer. Still in process of signing
Research Partnerships
In Progress
Established collaboration with the Center for Mental Health Innovation.
Pilot Launch
September
Launching our minimum viable product with core functionality for select partners.
Scientific Evidence
November
Upcoming study demonstrating effectiveness of our AI diagnostic approach.
Broad Launch
Q1 2026
Full public release making affordable diagnoses accessible to all families.
Our Team
Neil Natarajan
Founder & CEO
- Oxford PhD in Human-Centred AI
- Former research consultant at Schmidt Futures and the Ellison Institute of Technology
- Published researcher on AI, ADHD
Xavier Roberts-Gaal
Member of Technical Staff
- Harvard Psychology PhD candidate
- National Defense Science Fellow
- Former McKinsey London consultant
Sruthi Viswanathan
Member of Technical Staff
- Oxford PhD candidate in Human-Centred AI with a focus on mental health
- Former UX Research and Design Lead at Limbic AI
- Former UX Researcher at Google
Advisors
Professor Joel Nigg, PhD
Co-director, Center for Mental Health Innovation
Professor of Psychiatry, Oregon Health and Science University Division of Clinical Psychology
Alexandra Crew
Corporate Strategy Director at SCAN Group
Former EY-Parthenon strategy consultant
Oxford MSc with a focus in healthcare AI ethics
Professor Michelle Marie Martel
Chair, University of Kentucky Department of Psychology
Author, The Clinician's Guide to Oppositional Defiant Disorder: Symptoms, Assessment, and Treatment